8-K
filed February 13, 2025, 6:59 PM ET
ticker OVID
CIK 0001636651
other material
confidence high
sentiment negative
materiality 0.75
Ovid Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Ovid Therapeutics Inc.
- Received Nasdaq notice on Feb 10, 2025, that average closing bid price was below $1.00 for 31 consecutive trading days.
- Company has 180 days, until Aug 11, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.
- No immediate impact on listing; common stock continues to trade on Nasdaq while options to cure are explored.
- If not cured by Aug 11, Ovid may seek a second 180-day period by transferring to Nasdaq Capital Market.
- Failure to cure could lead to delisting, with appeal rights to a Nasdaq Hearings Panel.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-25-026192
- form_type
- 8-K
- ticker
- OVID
- cik
- 0001636651
- company_name
- Ovid Therapeutics Inc.
- filed_at
- 2025-02-13T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:04.263909+00:00
- generated_at
- 2026-05-26T22:19:32.124491+00:00
- sec_items
- ["3.01"]
- event_type
- other_material
- sentiment
- negative
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-25-026192
- json_url
- https://secwatch.observer/filing/0001193125-25-026192.json
- markdown_url
- https://secwatch.observer/filing/0001193125-25-026192.md
- text_url
- https://secwatch.observer/filing/0001193125-25-026192.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/d385884d8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ADTX
Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11
Aditxt, Inc.
May 29, 2026, 4:21 PM ET
other_material
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
Comparable filing
May 27, 2026, Aditxt, Inc. (the “Company”)
received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market
LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s
Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum
stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)
(the “Stockholders’ Equity Requirement”). The Letter further
Filing page
SEC filing
LIMN
Liminatus Pharma receives Nasdaq delisting notice; appeals filed
Liminatus Pharma, Inc.
May 27, 2026, 4:30 PM ET
other_material
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
Comparable filing
May 20, 2026, the Company received a notice
from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will
be delisted from The Nasdaq Global Mark
Filing page
SEC filing
TNON
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Tenon Medical, Inc.
May 22, 2026, 5:15 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
Comparable filing
May 21, 2026, Tenon Medical, Inc. (the “Company”)
received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying
the Company that it is no longer in compliance with the
Filing page
SEC filing
AGAE
AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K
Allied Gaming & Entertainment Inc.
May 21, 2026, 9:40 PM ET
other_material
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
Comparable filing
May 19, 2026, All In FutureTech Alliance,
Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)
from the Listing Qualifications Department (the “Staff”) of
Filing page
SEC filing
PMI
Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices
Picard Medical, Inc.
May 21, 2026, 4:15 PM ET
other_material
Items 2.02, 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
Comparable filing
reviously disclosed, on May
8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together
with the May 15 Notice, the “ Notices ”). In connection with the
Filing page
SEC filing
SNYR
Synergy CHC receives Nasdaq delisting notice for bid price below $1.00
Synergy CHC Corp.
May 18, 2026, 9:01 AM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
Comparable filing
May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of
The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing
Filing page
SEC filing
GCTK
Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18
Glucotrack, Inc.
May 15, 2026, 4:45 PM ET
other_material
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
Comparable filing
May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March
31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders’
Filing page
SEC filing
ISPC
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
iSpecimen Inc.
May 13, 2026, 5:00 PM ET
other_material
Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average
Comparable filing
minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.